Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?

Advanced epithelial ovarian cancer has a poor prognosis, but targeted therapies have been developed and are providing new hope. We reviewed recent results with PARP inhibitors as treatment and/or maintenance therapy following chemotherapy in newly diagnosed advanced ovarian cancer. Data confirm the...

Descripción completa

Detalles Bibliográficos
Autores: DiSilvestro, P. (Paul)|||/items/baa12800-3093-4db8-b395-cf4602412ed2, Colombo, N. (Nicoletta)|||/items/82e62d1e-e826-4c0f-809f-1a9fec13be3e, Harter, P. (P.)|||/items/262661b2-4b5b-463b-a599-bbc50796f3ca, González-Martín, A. (Antonio)|||/items/47e72e63-32d3-4a8a-91d5-2624d704fb4e, Ray-Coquard, I. (Isabelle)|||/items/942f3eb2-dcc1-4420-a88b-4222f6aeec45, Coleman, R.L. (Robert L.)|||/items/ba6aa402-ee1c-48e2-b247-d8e45e4cecb3
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/111319
Acceso en línea:https://hdl.handle.net/10171/111319
Access Level:acceso abierto
Palabra clave:PARP inhibitor
Ovarian cancer
BRCA mutation
Homologous recombination deficiency
id ES_c5741d7fc6c9b8a8a674179992c52ec7
oai_identifier_str oai:dadun.unav.edu:10171/111319
network_acronym_str ES
network_name_str España
repository_id_str
spelling Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?DiSilvestro, P. (Paul)|||/items/baa12800-3093-4db8-b395-cf4602412ed2Colombo, N. (Nicoletta)|||/items/82e62d1e-e826-4c0f-809f-1a9fec13be3eHarter, P. (P.)|||/items/262661b2-4b5b-463b-a599-bbc50796f3caGonzález-Martín, A. (Antonio)|||/items/47e72e63-32d3-4a8a-91d5-2624d704fb4eRay-Coquard, I. (Isabelle)|||/items/942f3eb2-dcc1-4420-a88b-4222f6aeec45Coleman, R.L. (Robert L.)|||/items/ba6aa402-ee1c-48e2-b247-d8e45e4cecb3PARP inhibitorOvarian cancerBRCA mutationHomologous recombination deficiencyAdvanced epithelial ovarian cancer has a poor prognosis, but targeted therapies have been developed and are providing new hope. We reviewed recent results with PARP inhibitors as treatment and/or maintenance therapy following chemotherapy in newly diagnosed advanced ovarian cancer. Data confirm the benefit of PARP inhibitors in this setting, especially in subgroups with genomic instability. We describe the implications of these trial results for clinical practice, focusing on the need for a personalized treatment approach based on biomarker profile and other factors, including tolerability, cost considerations, and physician and patient preference. We have developed a systemic treatment algorithm for newly diagnosed advanced ovarian cancer, intended as a tool for clinicians to aid decision making in their daily practice. We also consider areas of future research, such as exploring further options for patients whose disease relapses following PARP inhibitor treatment.MDPIDadun. Depósito Académico Digital Universidad de Navarra20212021-01-0120212021-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/111319reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/1113192026-06-21T12:47:57Z
dc.title.none.fl_str_mv Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?
title Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?
spellingShingle Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?
DiSilvestro, P. (Paul)|||/items/baa12800-3093-4db8-b395-cf4602412ed2
PARP inhibitor
Ovarian cancer
BRCA mutation
Homologous recombination deficiency
title_short Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?
title_full Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?
title_fullStr Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?
title_full_unstemmed Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?
title_sort Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?
dc.creator.none.fl_str_mv DiSilvestro, P. (Paul)|||/items/baa12800-3093-4db8-b395-cf4602412ed2
Colombo, N. (Nicoletta)|||/items/82e62d1e-e826-4c0f-809f-1a9fec13be3e
Harter, P. (P.)|||/items/262661b2-4b5b-463b-a599-bbc50796f3ca
González-Martín, A. (Antonio)|||/items/47e72e63-32d3-4a8a-91d5-2624d704fb4e
Ray-Coquard, I. (Isabelle)|||/items/942f3eb2-dcc1-4420-a88b-4222f6aeec45
Coleman, R.L. (Robert L.)|||/items/ba6aa402-ee1c-48e2-b247-d8e45e4cecb3
author DiSilvestro, P. (Paul)|||/items/baa12800-3093-4db8-b395-cf4602412ed2
author_facet DiSilvestro, P. (Paul)|||/items/baa12800-3093-4db8-b395-cf4602412ed2
Colombo, N. (Nicoletta)|||/items/82e62d1e-e826-4c0f-809f-1a9fec13be3e
Harter, P. (P.)|||/items/262661b2-4b5b-463b-a599-bbc50796f3ca
González-Martín, A. (Antonio)|||/items/47e72e63-32d3-4a8a-91d5-2624d704fb4e
Ray-Coquard, I. (Isabelle)|||/items/942f3eb2-dcc1-4420-a88b-4222f6aeec45
Coleman, R.L. (Robert L.)|||/items/ba6aa402-ee1c-48e2-b247-d8e45e4cecb3
author_role author
author2 Colombo, N. (Nicoletta)|||/items/82e62d1e-e826-4c0f-809f-1a9fec13be3e
Harter, P. (P.)|||/items/262661b2-4b5b-463b-a599-bbc50796f3ca
González-Martín, A. (Antonio)|||/items/47e72e63-32d3-4a8a-91d5-2624d704fb4e
Ray-Coquard, I. (Isabelle)|||/items/942f3eb2-dcc1-4420-a88b-4222f6aeec45
Coleman, R.L. (Robert L.)|||/items/ba6aa402-ee1c-48e2-b247-d8e45e4cecb3
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv PARP inhibitor
Ovarian cancer
BRCA mutation
Homologous recombination deficiency
topic PARP inhibitor
Ovarian cancer
BRCA mutation
Homologous recombination deficiency
description Advanced epithelial ovarian cancer has a poor prognosis, but targeted therapies have been developed and are providing new hope. We reviewed recent results with PARP inhibitors as treatment and/or maintenance therapy following chemotherapy in newly diagnosed advanced ovarian cancer. Data confirm the benefit of PARP inhibitors in this setting, especially in subgroups with genomic instability. We describe the implications of these trial results for clinical practice, focusing on the need for a personalized treatment approach based on biomarker profile and other factors, including tolerability, cost considerations, and physician and patient preference. We have developed a systemic treatment algorithm for newly diagnosed advanced ovarian cancer, intended as a tool for clinicians to aid decision making in their daily practice. We also consider areas of future research, such as exploring further options for patients whose disease relapses following PARP inhibitor treatment.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/111319
url https://hdl.handle.net/10171/111319
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418989913899008
score 15,81155

Similares en LA Referencia